Bfw, tada, I agree with your take on the value of the IP wrt to ckd and/or dementia success.

After the effects on eGFR and ALP were found in the post hoc analysis and Dr KZ’s excitement around this I, as a non-science person, have never understood why the ckd angle did not become a much higher priority.

I also did a previous post on this, a few years back, after Dr KZ’s first talk when he had just joined the RVX team. A huge market and it seems to me that all that is needed for ckd success is for Apabetalone to repeat what already occurred in the previous trials wrt effects on eGFR and ALP. Jmo